Acadia Pharma (ACAD) Reports Positive Top-line Results from the Pivotal Phase 3 Lavender Trial of Trofinetide in Rett Syndrome
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Acadia Pharmaceuticals (ACAD) PT Raised to $28 at Goldman Sachs
December 7, 2021 6:39 AM ESTGoldman Sachs analyst Salveen Richter raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $28.00 (from $25.00) while maintaining a Neutral rating.
... MoreAcadia Pharmaceuticals (ACAD) PT Raised to $26 at Mizuho Securities
December 7, 2021 6:30 AM ESTMizuho Securities analyst Vamil Divan raised the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $26.00 (from $24.00) while maintaining a Neutral rating.
The analyst commented, "Acadia has released top-line data for their pipeline asset trofinetide for the treatment of Rett syndrome. While... More
Acadia’s (ACAD) Rett Syndrome Data Adequate for Approval, Stock Gains Are Justified - Analyst
December 7, 2021 6:14 AM ESTOn December 6th, after market closed, Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) announced positive top-line results from the pivotal, Phase 3 Lavender study evaluating the efficacy and safety of trofinetide in 187 girls and young women aged 5-20 years with Rett syndrome.Acadia Pharma (NASDAQ: ACAD)
The... More
